{"entity":{"id":"inhibrx","kind":"company","name":"Inhibrx Biosciences","aka":[],"tldr":"Inhibrx Biosciences is a San Diego antibody company testing two cancer drugs: ozekibart, which triggers a self-destruct receptor on tumour cells in bone cancers such as Ewing sarcoma, and an OX40 antibody that boosts immune cells. Sanofi bought its sister lung disease drug in 2024.","summary":"Inhibrx Biosciences is a La Jolla, California clinical-stage company that engineers multivalent biologics. Ozekibart (INBRX-109) is a tetravalent DR5 (death receptor 5) agonist designed to induce tumour-selective programmed cell death and is enrolling patients with Ewing sarcoma in phase 1; INBRX-106 is a hexavalent OX40 agonist designed to promote receptor hyperclustering, in phase 1/2 and phase 2/3 trials. In January 2024 the predecessor Inhibrx, Inc. agreed to sell INBRX-101, a recombinant alpha-1 antitrypsin for alpha-1 antitrypsin deficiency, to Sanofi for 30 US dollars per share in cash plus a 5 US dollar contingent value right (about 2.2 billion US dollars aggregate value). Immediately before that merger closed on 30 May 2024, the non-101 assets (INBRX-105, INBRX-106, INBRX-109) were spun out into Inhibrx Biosciences, which received 200 million US dollars in cash, has Sanofi as an 8 percent holder and trades on Nasdaq as INBX.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://inhibrx.com/"},{"label":"Pipeline","url":"https://inhibrx.com/pipeline/"},{"label":"Sanofi transaction announcement (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1739614/000110465924005727/tm243849d1_ex99-1.htm"},{"label":"Completion 8-K (SEC)","url":"https://www.sec.gov/Archives/edgar/data/1739614/000110465924066650/tm243190d20_8k.htm"}],"tags":[],"related":[],"cancers":["sarcoma"],"sections":["targeted-therapy","immunotherapy"],"technologies":["monoclonal-antibody"],"targets":[],"drugs":["inbrx-106"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct04198766"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Chondrosarcoma and INBRX-105 status not confirmed from the fetched pipeline page. Inhibrx's own IPO (2020) not sourced."],"hq":"La Jolla, CA","country":"US","companyType":"biotech","website":"https://inhibrx.com/","ticker":"INBX","stage":"public","investors":[],"funding":[{"round":"Acquisition","year":2024,"amountUsd":2200000000,"source":"https://www.sec.gov/Archives/edgar/data/1739614/000110465924005727/tm243849d1_ex99-1.htm","note":"Predecessor Inhibrx, Inc. sold its INBRX-101 (alpha-1 antitrypsin) asset to Sanofi for about 2.2 billion US dollars aggregate value; oncology assets were spun out into Inhibrx Biosciences, capitalised with 200 million US dollars from Sanofi; completed 30 May 2024"}]},"route":"/companies/inhibrx/","neighbours":{"cancer":[{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"drug":[{"id":"inbrx-106","kind":"drug","name":"INBRX-106","route":"/drugs/inbrx-106/"}],"trial":[{"id":"nct06295731","kind":"trial","name":"INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC","route":"/trials/nct06295731/"},{"id":"nct04198766","kind":"trial","name":"Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalen","route":"/trials/nct04198766/"}]}}